Intrommune Therapeutics is a specialty biopharmaceutical company located in New York, NY, an emerging hub of innovative life science companies.
Intrommune’s team of scientific and pharmaceutical development experts work with researchers at leading academic centers to advance new breakthroughs in order to stop the food allergy epidemic.
Our goal in developing the oral mucosal immunotherapy (OMIT) platform for food allergies is to find a long-term solution for the 220 million, including 9 million U.S. adults and 6 million U.S. children, who suffer from this life-altering condition.
Michael Nelson, JD, Chief Executive Officer: Mr. Nelson graduated from Cornell University and received his J.D. from New York University School of Law. He has a background in law, finance and management. Previously, he was an analyst at Barclays Capital and ING, was an investment banker at Westwood Capital and CIBC World Markets and practiced law at Willkie Farr & Gallagher and Dewey Ballantine. Mr. Nelson is currently CFO at Allovate Therapeutics, CFO at at Immunovent Diagnostics, and a senior healthcare advisor to Westwood Capital, LLC.
Erick Berglund, PhD, Chief Scientific Officer: Dr. Berglund received his BS and MS from the University of N.H. and Boston University School of Medicine, respectively, then received his PhD in biochemistry from Goethe University in Frankfurt, Germany. He initially worked as a researcher at Sanofi‐Aventis, then became a USPTO registered patent agent, going on to work in business development and strategy at Kyorin Pharmaceuticals, and then as CEO of Vaxiva KK, a Tokyo-based vaccine company. He is currently the CEO of Allovate Therapeutics. Prior to launching Allovate Therapeutics, Dr. Berglund was a Medical Strategy Director at H4B Chelsea, a global healthcare communications consultancy in NYC.
Anthony Robinson, MS, CRNP, MBA, Chief Operating Officer: Mr. Robinson received his BS from Cornell University, his MS from MCP Hahnemann University and his MBA from The Pennsylvania State University. He worked in psychiatry and internal medicine services as a clinician, and then was responsible for clinical drug development of early through late state pharmaceutical products at Covance and Shire. Mr. Robinson currently is an advisor to Immunovent Diagnostics.
Danya Glabau, PhD, Medical Affairs Advisor: Ms. Glabau graduated from Cornell University with a Bachelor's degree in biology and received her PhD in Schence and Technology Studies (specializing in Medical Anthropology) from Cornell University. Her academic research examined food allergy patient experience, needs, and treatment decision making. Prior to joining Intrommune, conducted social science research and taught social science courses at Cornell University, and she previously worked in freelance healthcare public relations in New York, student services at Cornell University, and science communications and research coordination at a science museum and at Cornell University. Dr. Glabau is currently Director of Medical Affairs at Allovate Therapeutics and Associate Faculty at the Brooklyn Institute for Social Research.
Scientific Advisory Board
Wesley Burks, MD, FAAAAI: Dr. A. Wesley Burks is Executive Dean for the University of North Carolina at Chapel Hill School of Medicine, the Curnen Distinguished Professor of Pediatrics, and Executive Director of the UNC Food Allergy Initiative. Dr. Burks joins the Intrommune Advisory Board with 30 years’ experience conducting and leading clinical research on clinical presentations of food allergy, the properties of foods contributing to allergenicity, and food allergy immunotherapy, including pioneering research on sublingual immunotherapy for peanut allergy.
David Fleischer, MD: Dr. David Fleischer is Associate Professor of Pediatrics at the University of Colorado School of Medicine, Director of the Food Challenge Unit at Colorado Children’s Hospital, and board certified in both Allergy and Immunology and Pediatrics. He has led research sites for numerous multi-center studies, including NIH-NIAID funded CoFAR studies on peanut sublingual immunotherapy, egg oral immunotherapy, and the causes and progression of peanut allergies.
Matthew Greenhawt, MD, FAAP, MBA: Dr. Matthew Greenhawt is Assistant Professor of Pediatrics at the University of Colorado School of Medicine. He brings expertise in health services research, healthcare policy, and biostatistics. He has published over 50 articles on topics including the impact of food allergies on quality of life, vaccine safety, and food allergy healthcare policy, in addition to funded research into phenotypes in eosinophilic esophagitis and cost-effectiveness analysis.
William Reisacher, MD, Senior Medical Advisor: Dr. Reisacher graduated from Cornell University and received his medical degree from the Mount Sinai School of Medicine with distinction in research. His clinical expertise lies in the diagnosis and management of airborne and food allergies in adults and children. He completed his allergy fellowship through the American Academy of Otolaryngic Allergy (AAOA) in 2005. Dr. Reisacher is a General Otolaryngologist and Otolaryngic Allergist on the full-time Faculty of Weill Cornell Medical College, where he is Associate Professor of Otolaryngology and the Director of Allergy within the Department of Otolaryngology-Head and Neck Surgery. He has served on the Board of Directors of the AAOA, currently serves on the Board of Governors of the American Academy of Otolaryngology – Head and Neck Surgery and has lectured both nationally and internationally.